Stephen Gardell's Research Focus
Dr. Stephen Gardell aims to use his 20 years of experience in the pharmaceutical industry to drive the advancement of basic research discoveries to realize their potential therapeutic utility. In particular, he oversees the development and operation of several advanced technology core facilities: Metabolomics, Cardiometabolic Phenotyping, Histopathology, Cellular Imaging and the Vivarium at Lake Nona. His personal laboratory pursuits are centered around the role of LXR, a nuclear hormone receptor, and its endogenous oxysterol ligands in cardiovascular disease.
Stephen Gardell's Research Report
LXR agonists are known to exert remarkable efficacy in murine models of atherosclerosis. The current dogma is that efficacy arises from stimulation of reverse cholesterol transport whereby cholesterol is exported from the vessel wall (accumulated in “foam cells”) and transferred back to the liver where it is eliminated. This is probably not the whole story. The experiments in my laboratory are aimed at achieving a deeper understanding about the LXR-regulated mechanisms that operate at/in the vessel wall that serve to impede the development of atherosclerotic lesions.
Stephen Gardell's Bio
Stephen Gardell, Ph.D., received a B.S. degree in Biology from Boston College and a Ph.D. degree in Biochemistry from the Cornell University Graduate School of Medical Sciences. He performed postdoctoral studies at the University of California, San Francisco (UCSF) in the laboratory of Dr. William J. Rutter. Dr. Gardell joined Merck Research Laboratories (West Point, PA) in 1987, where he studied thrombosis and Alzheimer’s disease. His investigations of the secretases provided key insight into the pathophysiology of Alzheimer’s disease. In 2001, Dr. Gardell became the Director of Obesity Research at Bayer Research (West Haven, CT), where he pursued weight loss strategies involving appetite control and energy expenditure. In 2004, Dr. Gardell became Assistant Vice President, Cardiovascular Discovery Research at Wyeth where he directed programs in atherosclerosis, heart failure, thrombosis and arrhythmias. Dr. Gardell originally joined SBP in 2009.